Key result
Systemic serial administration of doxorubicin caused significant myocardial changes after the first course, whereas a single intravesical instillation did not cause laboratory or instrumental changes.
Why the study?
The toxic effects of intravenous doxorubicin on vital organs including the heart require further research, prompting an evaluation of cardiotoxicity manifestations and progression in patients with bladder cancer receiving systemic versus intravesical doxorubicin.
Does systemic versus intravesical doxorubicin administration cause cardiotoxicity in patients with bladder cancer?
Population
96 patients with bladder cancer
Comparison
Surgery alone vs systemic intravenous doxorubicin vs intravesical doxorubicin
Authors
Loading...
Doxorubicin cardiotoxicity in bladder cancer warrants caution; level 5 evidence leaves open need for larger studies.
Cohort (n=96)
Does systemic versus intravesical doxorubicin administration cause cardiotoxicity in patients with bladder cancer?
Systemic doxorubicin induces early signs of cardiotoxicity in bladder cancer patients, whereas intravesical administration appears safe from a cardiac perspective.
N. L. Hodovan (2021) conducted a cohort in Bladder cancer (n=96). Doxorubicin (systemic or intravesical) vs. Surgical treatment only (no doxorubicin) was evaluated on ECG data and biochemical markers of myocardial destruction. Systemic serial administration of doxorubicin caused significant myocardial changes after the first course, whereas a single intravesical instillation did not cause laboratory or instrumental changes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: